CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
Peripheral T-cell lymphoma (PTCL) is a highly heterogeneous and aggressive non-Hodgkin's
lymphoma. The incidence rate of PTCL in China is much higher than the global average, and
there is no unified standard treatment for initial PTCL. Currently, the CHOP regimen is
widely used as first-line treatment. However, the overall response rate is still low, and
effective therapies need to be explored. Epigenetics and genetics jointly determine critical
features of tumors, and exploring new treatment strategies and developing targeted drugs
based on deep understanding of the pathogenesis is of significant importance. The combined
application of DNMT inhibitors and HDAC inhibitors has strong scientific support. The Phase
II clinical study of Mitoxantrone Hydrochloride Liposome in treating relapsed or refractory
PTCL achieved positive results and regulatory approval. The CMOP regimen combining
Mitoxantrone Hydrochloride Liposome with Chidamide is worth exploring for initial PTCL
treatment.
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University